These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 10561241)

  • 1. Re-evaluation of benefits of BRCA1/2 testing.
    Knell ER; Presant CA
    J Clin Oncol; 1999 Jun; 17(6):1962. PubMed ID: 10561241
    [No Abstract]   [Full Text] [Related]  

  • 2. A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2.
    Ramus SJ; Friedman LS; Gayther SA; Ponder BA; Bobrow L; van der Looji M; Papp J; Olah E
    Nat Genet; 1997 Jan; 15(1):14-5. PubMed ID: 8988162
    [No Abstract]   [Full Text] [Related]  

  • 3. Adrenal tumors in BRCA1/BRCA2 mutation carriers.
    Barak F; Shiri-Svredlov R; Bruchim-Bar Sade R; Kruglikova A; Friedman E; Ben-Dor D; Goldberg I
    Am J Med Genet; 2001 Jan; 98(3):277-9. PubMed ID: 11169568
    [No Abstract]   [Full Text] [Related]  

  • 4. Simple and rapid detection of BRCA1 and BRCA2 mutations by multiplex mutagenically separated PCR.
    Chan PC; Wong BY; Ozcelik H; Cole DE
    Clin Chem; 1999 Aug; 45(8 Pt 1):1285-7. PubMed ID: 10430798
    [No Abstract]   [Full Text] [Related]  

  • 5. The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients.
    Chen-Shtoyerman R; Figer A; Fidder HH; Rath P; Yeremin L; Bar Meir S; Friedman E; Theodor L
    Br J Cancer; 2001 Feb; 84(4):475-7. PubMed ID: 11207040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NIH researchers receive cut-price BRCA test.
    Hollon T
    Nat Med; 2000 Jun; 6(6):610. PubMed ID: 10835655
    [No Abstract]   [Full Text] [Related]  

  • 7. BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials.
    Levy-Lahad E; Krieger M; Gottfeld O; Renbaum P; Klein G; Eisenberg S; Lahad A; Kaufman B; Catane R
    J Cell Biochem Suppl; 2000; 34():13-8. PubMed ID: 10762009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2.
    Grann VR; Whang W; Jacobson JS; Heitjan DF; Antman KH; Neugut AI
    J Clin Oncol; 1999 Feb; 17(2):494-500. PubMed ID: 10080590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer genes--what are the real risks?
    Easton D
    Nat Genet; 1997 Jul; 16(3):210-1. PubMed ID: 9207777
    [No Abstract]   [Full Text] [Related]  

  • 10. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
    Roa BB; Boyd AA; Volcik K; Richards CS
    Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. I1307K APC variant in non-Ashkenazi Jewish women affected with breast cancer.
    Nathanson KL; Antin-Ozerkis D; Couch FJ; Weber BL
    Am J Med Genet; 1999 Jul; 85(2):189-90. PubMed ID: 10406676
    [No Abstract]   [Full Text] [Related]  

  • 12. Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations.
    Wagner T; Stoppa-Lyonnet D; Fleischmann E; Muhr D; Pagès S; Sandberg T; Caux V; Moeslinger R; Langbauer G; Borg A; Oefner P
    Genomics; 1999 Dec; 62(3):369-76. PubMed ID: 10644434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations.
    Lal G; Liu G; Schmocker B; Kaurah P; Ozcelik H; Narod SA; Redston M; Gallinger S
    Cancer Res; 2000 Jan; 60(2):409-16. PubMed ID: 10667595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer.
    Schubert EL; Mefford HC; Dann JL; Argonza RH; Hull J; King MC
    Genet Test; 1997; 1(1):41-6. PubMed ID: 10464624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
    Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
    Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness analysis of genetic testing for breast and ovarian cancer susceptibility genes: BRCA1 and BRCA2.
    Kaldate R; Huston A; McCoy H; Cardeiro D; Noyes K
    Breast J; 2014; 20(3):325-6. PubMed ID: 24708220
    [No Abstract]   [Full Text] [Related]  

  • 17. Carrying a genetic passport for ovarian cancer.
    Modan B
    Lancet; 1996 Nov; 348(9038):1328. PubMed ID: 8918274
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic testing for breast cancer susceptibility: frequency of BRCA1 and BRCA2 mutations.
    Ganguly A; Leahy K; Marshall AM; Dhulipala R; Godmilow L; Ganguly T
    Genet Test; 1997; 1(2):85-90. PubMed ID: 10464631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Brca1 and Brca2 proteins and tumor pathogenesis.
    Ingvarsson S
    Anticancer Res; 1999; 19(4B):2853-61. PubMed ID: 10652564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [BRCA1 and BRCA2--breast cancer susceptibility genes].
    Dagan E; Gershoni-Baruch R
    Harefuah; 1997 Nov; 133(10):455-7. PubMed ID: 9418320
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.